Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Pierre-Fabre-OBGEMSA

More Like This

PR Newswire associated0

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.

PR Newswire associated0

UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

PR Newswire associated0

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

PR Newswire associated0

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)

PR Newswire associated0

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union